Sarah Sammons/medicine.duke.edu
Mar 31, 2025, 08:53
Sarah Sammons: A few highlights from my ADC resistance talk at LACOG-GBECAM 2025
Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
“A few highlights from my ADC resistance talk at LACOG-GBECAM 2025.
- T-DXd works after T-DM1, diff payload, stronger ADC
- 2nd TOP1 ADC performs inferiorly, unclear who benefits >1
- Mutations in TROP2 and TOP1–> resistance
- Downregulation of target occurs after T-DXd treatment
- We need new ADCs with diverse payloads
I love Brazil!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53